OrphoMed

OrphoMed

OrphoMed is a clinical-stage biotechnology company with a proprietary dimer therapeutics platform. The company is focused on developing treatments for patients with gastrointestinal disorders.

All edits

Edits on 6 Oct, 2020
Golden AI"Funding autocalculation"
Golden AI edited on 6 Oct, 2020
Edits made to:
Infobox (+1 properties)
Infobox
Latest funding round date
May 2017
Edits on 20 Jul, 2020
Edita Rexha
Edita Rexha approved a suggestion from Golden's AI on 20 Jul, 2020
Edits made to:
Article (+21/-21 characters)
Article

In May 2017, OrphoMed raised $39 million Series A financing. The round was led by New Enterprise Associates, and co-led by existing seed investor Takeda Ventures, Inc.Takeda Ventures, Inc., with participation from other prior investors: Pappas Capital, through its newest fund, Pappas Ventures V; Relativity Healthcare Partners and the Mario Family Fund.

Edits on 17 Jul, 2020
Golden AI"Funding autocalculation"
Golden AI edited on 17 Jul, 2020
Edits made to:
Infobox (+1 properties)
Infobox
Total funding amount (USD)
39,000,000
Edits on 7 Dec, 2019
Jude Gomila"Approved suggestion #716187"
Jude Gomila edited on 7 Dec, 2019
Edits made to:
Infobox (+1 properties)
Infobox
Industry
Biopharmaceutical
Edits on 11 Oct, 2019
Golden AI
Golden AI edited on 11 Oct, 2019
Edits made to:
Infobox (+1 properties)
Infobox
Funding rounds
OrphoMed funding round, May 2017
Edits on 7 Oct, 2019
Reys Phillips
Reys Phillips edited on 7 Oct, 2019
Edits made to:
Infobox (+4 properties)
Infobox
Industry
Biotechnology
Location
San Francisco
Legal name
OrphoMed Inc.
Edits on 8 Jul, 2019
Will Suter
Will Suter approved a suggestion from Golden's AI on 8 Jul, 2019
Edits made to:
Article (+14/-14 characters)
Article

In May 2017, OrphoMed raised $39 million Series A financing. The round was led by New Enterprise Associates, and co-led by existing seed investor Takeda Ventures, Inc., with participation from other prior investors: Pappas CapitalPappas Capital, through its newest fund, Pappas Ventures V; Relativity Healthcare Partners and the Mario Family Fund.

Dawson Sewell
Dawson Sewell edited on 7 Jul, 2019
Edits made to:
Topic thumbnail

OrphoMed

OrphoMed is a clinical-stage biotechnology company with a proprietary dimer therapeutics platform. The company is focused on developing treatments for patients with gastrointestinal disorders.

Edits on 11 Apr, 2019
Carla Faraguna
Carla Faraguna approved a suggestion from Golden's AI on 11 Apr, 2019
Edits made to:
Article (+25/-25 characters)
Article

In May 2017, OrphoMed raised $39 million Series A financing. The round was led by New Enterprise AssociatesNew Enterprise Associates, and co-led by existing seed investor Takeda Ventures, Inc., with participation from other prior investors: Pappas Capital, through its newest fund, Pappas Ventures V; Relativity Healthcare Partners and the Mario Family Fund.

Carla Faraguna
Carla Faraguna approved a suggestion from Golden's AI on 11 Apr, 2019
Edits made to:
Infobox (+1 properties)
Infobox
Industry
Microbiome
Edits on 9 Jan, 2019
Golden AI
Golden AI edited on 9 Jan, 2019
Edits made to:
Infobox (+1 properties)
Infobox
Is a
Company
Edits on 10 Dec, 2018
Carla Faraguna
Carla Faraguna edited on 10 Dec, 2018
Edits made to:
Infobox (+1 properties)
Categories (+2 topics)
Infobox
Categories
Edits on 16 Oct, 2018
Carla Faraguna
Carla Faraguna edited on 16 Oct, 2018
Edits made to:
Description (+192 characters)
Article (+693 characters)
Related Topics (+1 topics)

OrphoMed

OrphoMed is a clinical-stage biotechnology company with a proprietary dimer therapeutics platform. The company is focused on developing treatments for patients with gastrointestinal disorders.

Article

OrphoMed is a clinical-stage biotechnology company with a proprietary dimer therapeutics platform. The company is focused on developing treatments for patients with gastrointestinal disorders.

In May 2017, OrphoMed raised $39 million Series A financing. The round was led by New Enterprise Associates, and co-led by existing seed investor Takeda Ventures, Inc., with participation from other prior investors: Pappas Capital, through its newest fund, Pappas Ventures V; Relativity Healthcare Partners and the Mario Family Fund.

...

The capital will be used to advance the clinical development of OrphoMed's lead candidate, ORP-101, for the treatment of irritable bowel syndrome with diarrhea (IBS-D).

Related Topics
Edits on 21 Aug, 2018
Carla Faraguna"Initial topic creation"
Carla Faraguna created this topic on 21 Aug, 2018
Edits made to:
Topic thumbnail

 OrphoMed

OrphoMed is a clinical-stage biotechnology company with a proprietary dimer therapeutics platform. The company is focused on developing treatments for patients with gastrointestinal disorders.

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.